This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Humana (HUM) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Humana (HUM) closed the most recent trading day at $447.26, moving +1.48% from the previous trading session.
Teladoc (TDOC) & Microsoft Partner to Reduce Administrative Woes
by Zacks Equity Research
Teladoc (TDOC) collaborates with Microsoft, enabling automatic clinical documentation with the help of AI.
Acadia Healthcare's (ACHC) New Facility Boosts Pennsylvania Reach
by Zacks Equity Research
Acadia Healthcare (ACHC) commences operations at one of the two hospitals, which form a part of its JV with Geisinger. The company is committed to offer enhanced behavioral health services in Pennsylvania.
Will Humana (HUM) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Humana (HUM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks.com featured highlights include Humana, The TJX Companies, Sunstone Hotel Investors, Atmos Energy and MINISO Group Holding
by Zacks Equity Research
Humana, The TJX Companies, Sunstone Hotel Investors, Atmos Energy and MINISO Group Holding are part of the Zacks Screen of the Week article.
Humana (HUM) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Humana (HUM) closed at $424.29 in the latest trading session, marking a -0.19% move from the prior day.
Here's Why You Should Hold Centene (CNC) Stock for Now
by Zacks Equity Research
Strong membership growth, contract wins, accretive acquisitions and the streamlining of businesses poise Centene (CNC) well for growth.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
5 Low-Leverage Stocks to Buy as Inflation Cools Down Slightly
by Aparajita Dutta
The equity market can be volatile at times and as an investor, if you want to play safe, buy stocks like HUM, TJX, SHO, ATO and MNSO.
Are Options Traders Betting on a Big Move in Humana (HUM) Stock?
by Zacks Equity Research
Investors need to pay close attention to Humana (HUM) stock based on the movements in the options market lately.
The Zacks Analyst Blog Highlights Honeywell International, Humana, Keurig Dr Pepper, NextEra Energy and The Coca-Cola
by Zacks Equity Research
Honeywell International, Humana, Keurig Dr Pepper, NextEra Energy and The Coca-Cola are part of the Zacks top Analyst Blog.
Why You Should Add Humana (HUM) Stock to Your Portfolio Now
by Zacks Equity Research
Humana's (HUM) strength in Individual Medicare Advantage business and state-based contract wins are likely to be major tailwinds.
Buy 5 Underperformers of 1H That Are Set to Be on a Roll in 2H
by Nalak Das
We have narrowed our search to five U.S. corporate bigwigs with negative returns in stock prices in the first half of 2023. These are: HON, HUM, KO, KDP, NEE.
Humana (HUM) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Humana (HUM) closed the most recent trading day at $440.99, moving -0.9% from the previous trading session.
UnitedHealth's (UNH) Suffering Continues: Should You Hold Tight?
by Zacks Equity Research
Each sub-segment of Optum, UnitedHealth's (UNH) health service business, is expected to continue delivering a solid performance, driving the overall segment's growth.
Molina (MOH) to Buy Bright Health's California Medicare Business
by Zacks Equity Research
Molina's (MOH) Brand New Day and Central Health Plan of California buyout complements Molina's Medicaid footprint and aligns with its 2024 Medi-Cal plan.
Humana (HUM) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Humana (HUM) closed at $447.13 in the latest trading session, marking a +0.74% move from the prior day.
Down -13.84% in 4 Weeks, Here's Why You Should You Buy the Dip in Humana (HUM)
by Zacks Equity Research
Humana (HUM) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Is Humana (HUM) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Humana (HUM) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Should Value Investors Buy Humana (HUM) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
UnitedHealth Group (UNH) Expands Home Healthcare Business
by Zacks Equity Research
UnitedHealth Group (UNH) boosts home healthcare presence with the acquisition of Amedisys for $3.3 billion
UnitedHealth's (UNH) Optum Rx Makes Patient Care Affordable
by Zacks Equity Research
UnitedHealth Group, Inc's. (UNH) Optum Rx is set to offer three biosimilar alternatives for HUMIRA effective Jul 1, providing affordability in patient care.
Profiting from the 3rd Wave of the App Economy
by Andrew Rocco
The third wave of the application economy will be driven by the onset of VR headsets and Artificial Intelligence. Because of their partnerships with tech juggernauts, two companies stand to benefit the most.
Humana's (HUM) CenterWell Unit Plans to Expand in Tennessee
by Zacks Equity Research
Humana's (HUM) CenterWell business is likely to benefit from its promising plans to expand across middle Tennessee this year.
Here's Why Buying Brookdale (BKD) Stock is a Prudent Move Now
by Zacks Equity Research
For the second quarter, Brookdale (BKD) expects RevPAR growth to be in the range of 11.5-12%.